Avacta Group plc (AVCT) Shares Early AVA6103 Phase 1 Safety/PK And PDAC Preclinical Data

Avacta detailed FOCUS-01 Phase 1 design and preclinical PDAC data for AVA6103, noting preliminary safety and PK consistent with models and tolerability up to ~50% above conventional exatecan MTD. Initial efficacy readout is targeted in H1 2027.Material DetailsContext by AI AnalystThis is early clin…